Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37316728/
Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase...
Conclusions/Relevance: Isatuximab PK parameters were within the previously reported range, suggesting that VRd does not alter the PK of isatuximab. These data support additional studies of isatuximab in NDMM, such as the Phase 3 IMROZ study (Isa-VRd vs VRd).
Widespread presentation of brown tumors mimicking multiple myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37286908/
Brown tumors or osteitis fibrosa cystica has become a rare presentation of primary hyperparathyroidism in up-to-date clinical practice. Here, we describe a case of longstanding untreated hyperparathyroidism presenting itself with...
Conclusions/Relevance: Here, we describe a case of longstanding untreated hyperparathyroidism presenting itself with brown tumors in a 65-year-old patient. During the diagnostic work-up of this patient, bone SPECT/CT and 18F-FDG-PET/CT revealed multiple widespread osteolytic lesions. Differentiating from other bone tumors such as multiple...
Single-cell technologies in multiple myeloma: new insights into disease pathogenesis and translational implications - Biomarker Research
Source : https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-023-00502-8
Multiple myeloma (MM) is a hematological malignancy characterized by clonal proliferation of plasma cells. Although therapeutic advances have been made to improve clinical outcomes and to prolong patients' survival in...
Conclusion: In closing, SCS technologies have already revolutionized many aspects of cancer translational research and are prepared to have a greater impact in clinic. As the last decade has seen NGS technologies transform modern oncology, we believe that single-cell methodologies will influence many areas of MM medicine in the same way, and...
Mechanism of action of Asparagus officinalis extract against multiple myeloma using bioinformatics tools, in silico and in vitro study
Source : https://www.frontiersin.org/articles/10.3389/fphar.2023.1076815/full
Introduction: Asparagus (Asparagus officinalis) is a perennial flowering plant species. Its main components have tumor-prevention, immune system-enhancement, and anti-inflammation effects. Network pharmacology is a powerful approach that is being applied...
Discussion: In this study, the anti-cancer activity of asparagus against MM was demonstrated using network pharmacology, and potential pharmacological mechanisms were inferred using in vitro experimental data.
Liquid biopsies and minimal residual disease in lymphoid malignancies - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37228488/
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous...
Conclusion: Liquid biopsy for MRD testing using blood is rapidly evolving in the field of lymphoid malignancies. Most advancement is seen in the evaluation, management and in the post-therapy monitoring of ALL leading to routine clinical utilization. Liquid biopsy based MRD testing in common non-Hodgkin’s lymphoma such as diffuse large B...